AIM
PTGX icon

Alambic Investment Management’s Protagonist Therapeutics PTGX Stock Holding History

Alambic Investment Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-14,940
Closed -$188K – 366
2019
Q1 		$188K Hold
14,940
– – 0.08% 289
2018
Q4 		$101K Sell
14,940
-50,188
-77% -$398K 0.04% 277
2018
Q3 		$670K Sell
65,128
-168,925
-72% -$1.45M 0.53% 61
2018
Q2 		$1.57M Buy
234,053
+196,353
+521% +$1.51M 0.43% 80
2018
Q1 		$324K Buy
+37,700
New +$710K 0.05% 365

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Alambic Investment Management's PTGX Position: Q2 2019 in Review

Alambic Investment Management sold out of Protagonist Therapeutics (PTGX) in Q2 2019, closing a stake of 14,940 shares — an estimated $188K sold.

Alambic Investment Management first reported a position in PTGX in Q1 2018 and held it in 5 quarters. The position peaked at $1.57M in Q2 2018. 66 funds tracked by Wall St. Rank hold PTGX as of Q2 2019.

  • Alambic Investment Management reported no remaining Protagonist Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Alambic Investment Management sold 14,940 Protagonist Therapeutics shares in Q2 2019, an estimated $188K.
  • Alambic Investment Management first reported a position in Protagonist Therapeutics in Q1 2018 and held it in 5 quarters.
  • Alambic Investment Management's Protagonist Therapeutics position peaked at $1.57M in Q2 2018.
  • 66 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2019.

Based on Alambic Investment Management's 13F filing for Q2 2019, filed 13 Aug 2019.